Reza Shojaei: On The 2nd Day of IPAW 2025, Let’s Focus on Patients, The Real Reason Plasma Matters!
Reza Shojaei, Chief Operating Officer at Canadian Plasma Resources, shared on LinkedIn:
”On the second day of IPAW 2025, let’s focus on patients, the real reason plasma matters.
Plasma-derived medicines treat life-threatening conditions such as primary immune deficiencies, hemophilia, and hereditary angioedema.
For many, these therapies are not optional; they are the only available treatment, turning what used to be fatal diseases into manageable conditions.
Every donation ensures someone, somewhere, gets another chance at health, at family life, at simply living fully.
Behind each unit of plasma is a powerful chain: a donor’s generosity, a patient’s survival, and then a family’s hope.
Let’s use this week to amplify the voices of patients and remind the world that plasma saves lives every single day.
If you know someone whose life has been touched by plasma therapies, share their story on social media, because awareness grows stronger when it’s personal.”
Stay updated on emerging topics in transfusion medicine with Hemostasis Today.
-
Jun 9, 2026, 17:55Can We Prevent Postpartum Blood Clots without Putting Most Women on Heparin? – RPTH Journal
-
Jun 9, 2026, 17:54Lucky Oseghale Oloboh: Health Is Power, Health Is Personal, and Health Is Our First Responsibility in Life’s Journey on Mother Earth
-
Jun 9, 2026, 17:53Ajay Samkaria: How ABO Subgroups Directly Impact Transfusion Safety
-
Jun 9, 2026, 17:51Alejandro González Veliz: Most Reported Aspirin Allergies Are Not True Hypersensitivity
-
Jun 9, 2026, 17:50Mary Cushman: It’s Time to Apply to Be on an ISTH SSC
-
Jun 9, 2026, 15:56Wolfgang Miesbach: A New Genetic Perspective on the Worldwide Burden of von Willebrand Disease
-
Jun 9, 2026, 15:34Shanon Marie Corsino: Nationwide Insights into Cancer-Associated Thrombosis in Filipino Patients
-
Jun 9, 2026, 15:20Murtuza Ali: Types of Blood Transfusions – A Quick Clinical Guide
-
Jun 9, 2026, 15:18Mital Jhaveri: TRACK Trial Findings Highlight the Unique Challenges of Advanced CKD